Intrommune Logo Only - 250k.jpg
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”
January 07, 2021 17:35 ET | Intrommune Therapeutics
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
October 20, 2020 10:00 ET | Intrommune Therapeutics
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal,...
Intrommune Logo Only - 250k.jpg
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies
October 08, 2020 09:50 ET | Intrommune Therapeutics
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies. The article,...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Featured at Upcoming Investor Conferences
October 05, 2020 14:55 ET | Intrommune Therapeutics
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Intrommune Logo Only - 250k.jpg
Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal
September 01, 2020 15:55 ET | Intrommune Therapeutics
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...
Intrommune Logo Only - 250k.jpg
Intrommune to Present at Biotech Showcase™ 2020
December 18, 2019 09:05 ET | Intrommune Therapeutics
New York, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics will attend and present at the upcoming Biotech Showcase™, which occurs during the annual J.P. Morgan Biotechnology...
Intrommune Logo Only - 250k.jpg
Intrommune Participates in 2019 Food Allergy Fund Summit
November 26, 2019 15:41 ET | Intrommune Therapeutics
New York, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment for peanut and other food allergies delivered...
Intrommune Logo Only - 250k.jpg
POISED Study Supports Risk of Cessation of Oral Immunotherapy for Peanut Allergy; PACE Study Indicates Safer Peanut Allergy Treatment Approaches are Needed
November 07, 2019 10:00 ET | Intrommune Therapeutics
New York, Nov. 07, 2019 (GLOBE NEWSWIRE) -- A major study recently published in The Lancet, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study),” further validates the...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote
September 16, 2019 14:25 ET | Intrommune Therapeutics
New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...